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Objective: Neonatal Lupus (NL) is a rare syndrome caused by placental transfer of
maternal anti-SSA/Ro and anti-La/SSB autoantibodies to the fetus. The rarity of this
condition requires the establishment of multidisciplinary registries in order to improve
our knowledge.
Method: Inclusion criteria in this retrospective study were the maternal confirmed
positivity for anti-SSA/Ro and/or anti-SSB/La antibodies, and the presence of II or III
degree congenital heart block (CHB) in utero or neonatal period (up to 27 days after birth).
Result: Eighty-nine cases of CHB were observed in 85 women with 88 pregnancies
that occurred between 1969 and 2017. CHB was mostly detected in utero (84 cases,
94.2%), while five cases were observed in the neonatal period. A permanent pacemaker
was implanted in 51 of 73 children born alive (69.8), whereas global mortality rate was
25.8% (23 cases): 16 in utero, five perinatal, and two during childhood. By univariate
analysis, factors associated with fetal death were pleural effusion (p = 0.005, OR > 100;
CI 95% 2.88->100 and hydrops (p= 0.003,OR= 14.09; CI 95% 2.01–122). Fluorinated
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steroids (FS) were administered in 71.4% pregnancies, and its use was not associated
with better survival. Some centers treated all cases with fluorinated steroids and some
centers did not treat any case. CHBwas initially incomplete in 24 fetuses, and of them five
cases of II degree block reverted to a lower degree block after treatments. Recurrence
rate in subsequent pregnancies was 17.6% (3 out of 17). A prophylactic treatment was
introduced in 10 of these 16 subsequent (58.8%) pregnancies, mostly with FS or high
dose intravenous immunoglobulins.
Conclusion: This is the first report from the Italian Registry of neonatal lupus/CHB.
The live birth rate was nearly 80%, with nearly two thirds of the children requiring the
implantation of a pacemaker. The management of fetuses diagnosed with CHB was
heterogeneous across Italian Centers. The registry at present is mainly rheumatological,
but involvement of pediatric cardiologists and gynecologists is planned.
Keywords: pregnancy, congenital heart block, neonatal lupus, outcome, risk factors, therapy
INTRODUCTION
Neonatal lupus (NL) is a rare disorder mainly caused by
the transplacental passage of maternal autoantibodies
anti-SSA/Ro and/or anti-SSB/La (1, 2), usually during the
second trimester of gestation (3, 4); these antibodies can
reach the fetal heart, inducing inflammation (macrophage
infiltration and giant cell formation), calcification, and
fibrosis, which lead to aberrant signal conduction at the
atrio-ventricular node. The most common manifestations
are cutaneous or cardiac, while liver damage or cytopenia
are less frequent. NL can occur in the offspring of
mothers with a diagnosis of connective tissue disease
(CTD), mostly Sjögren Syndrome (SS), or Systemic Lupus
Erythematosus (SLE), but most cases are reported in
asymptomatic women.
Cardiac involvement is usually irreversible and represents
the most feared manifestation. It is characterized by advanced
congenital heart block (CHB) (II or III degree) in an otherwise
structurally normal heart.
Anti-SSA/Ro autoantibodies are found in ∼85–90% of
mothers of children with CHB (1), and prospective studies
of pregnancies in anti-SSA/Ro positive patients estimated the
risk of CHB to be 1–2% (5, 6). Recurrence rate in subsequent
pregnancies is about 12–19% (1, 7, 8).
Several groups addressed the morbidity and mortality
associated with CHB in different countries (9–13). Mortality
ranges from 16 to 29%, whereas the rates of children
receiving pacemaker vary from 50 to 79%, frequently
within the first year of life. Studies are heterogeneous, also
including cases not associated with maternal antibodies
(9–14) (Table 1). The Italian Registry of Neonatal Lupus
(Lu.Ne registry) was created to collect data also in Italy,
supported by a grant from the Italian Society of Rheumatology.
The aim was to determine the mortality and morbidity
associated with CHB in an Italian cohort enrolling
women with a confirmed positivity for anti-SSA/Ro and/or
anti-SSB/La antibodies.
PATIENTS AND METHODS
Study Cohort
The Lu.Ne registry was created in 2016, partially funded by
the Italian Society of Rheumatology, after approval of the
Institutional Review Board of the Coordinating Center in Brescia.
Inclusion criteria were thematernal confirmed positivity for anti-
SSA/Ro and/or anti-SSB/La antibodies and the presence of II
or III degree CHB in utero or within the neonatal period (0–
27 days after birth) (15) documented by electrocardiography
and/or fetal echocardiography. For this study cases enrolled in
the registry up to May 2018 were included. Medical records of
pregnant women attending 11 Italian referral centers (mainly
Rheumatology or Internal Medicine Departments, whose ethical
committees approved the study) from 1969 to 2017 were
retrospectively evaluated. In cases of variability of CHB grade,
the most severe degree of CHB ever reached was considered
for statistical analysis. This study was performed according
to the principles of the Declaration of Helsinki with written
informed consent from all subjects and was approved by the Ethic
Committee of the Coordinating Center (approval number 2,417)
and the participating centers.
Data Collection and Definitions
Data were collected through an online electronic data sheet
prepared in a Research Electronic Data Capture (REDCap)
platform. Data obtained from medical files included: maternal
age at birth, ethnicity, obstetrical history, the presence of a
systemic connective tissue disease (CTD), an organ autoimmune
disease or other known obstetrical risk factors.
The following data were collected about the fetus/child: the
time of occurrence of CHB, the lowest prenatal ventricular and
atrial heart rate, the presence of endocardial fibroelastosis (EFE),
pericardial effusion, hydrops, dilated cardiomyopathy (DCM),
valvulopathy or other anomalies (including ventricular and
atrial-septal defects, intraauricular communication), treatment
for CHB (dose and duration), maternal, and fetal outcomes. For
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TABLE 1 | Outcome of infants with CHB in the present study and in five large international series of cases (9–13).
Lopes et al. (9) Eliasson et al. (10) Izmirly et al. (11) Levesque
et al. (12)
Van der Berg
et al. (13)
Present study
N. of fetuses 57 with normal
cardiac anatomy
175 325 202 in utero +12
in the neonatal
period
56 84 in utero +5 in
the neonatal
period
Total mortality 13 (23%) 27 (15%) 57 (17.5%) 49 (23%) 9 (16%) 23 (25.8%)
Mortality in utero 6 (10%) 16 (9%) 18 (6%) 27 (13%) 8 (14.2%) (five
additional cases of
termination of
pregnancies for
various reasons
16 (17.9%)
Perinatal mortality 7 (14%) 10 (6.2%) 39 (12.7%)
considered as 1 year
after birth
8 (4%) 1 (2.3) 5 (5.6%)
PM cumulative
prevalence
29 (56.7%) 102 (64%) 70% (the cumulative
probability)
148 (79%) 30 (70%) 51 (69.8%)
Late onset
cardiomiopathy
3 (5.6%) 8 (5.8%) Four cases of heart
transplantation
35 (18%) 6 (14%) 2 (2.2%)
Treated with FS 6 (10%) 67 (38%) 152 (47.8%) 79 (39%) 14 (27%) 60 (71.4%%)
Effects of FS None None on mortality;
possibly reversal on II
CHB
Possibly reversal on II
CHB
None None None on mortality;
possibly reversal
on II CHB
Reversal of II degree
CHB after FS
None In 3/7 fetuses treated
vs. 0/8 untreated
In 4/13 fetuses
treated vs. 1/8
untreated
In 1/13 treated vs.
1/11 untreated
In 2/14 treated vs.
1/42
Five cases, all
treated; see
footnote*
Variables associated
with death
Atrial rate <120 bpm,
ventricular rate <55
bpm, hydrops,
Detection <20 gw,
ventricular rate <50
bpm, hydrops,
impaired left
ventricular function
Earlier gestational
age, lower ventricular
rate, hydrops, EFE
Hydrops,
prematurity (<37
weeks gestation)
Not analyzed Hydrops, pleural
effusion
Survival rate at 10
years for a child born
alive
NA NA 86% 88% NA 90%
Maternal anti-SSA/Ro
antibodies
72% 80% of 162
pregnancies with
documented
antibody status
100% 99.5 % 89% 100%
*1 case regressed from II degree to variable CHB (alternating between I and II degree), 2 from II to I degree and 2 regression from II degree to no CHB. Three out of the five fetuses were
treated with a combined protocol composed by fluorinated steroids plus plasmapheresis plus IVIg, one received dexametasone plus plasmapheresis and one only dexametasone. NA,
not available; CHB, congenital heart block; EFE, endocardial fybroelastosis; DCM, dilated cardiomyopathy; FS, fluorinated steroids; bpm, beats per minute.
children, we collected information on pacemaker implantation
(PM), postnatal DCM, death, and other complications.
Fetal complications were defined according to common
definitions (10–13). Atrioventricular block (AVB)-II◦ was
defined as the intermittent mechanical dissociation of atrial and
ventricular activation diagnosed by M-mode echocardiography
and AVB-III◦ as the complete mechanical dissociation of atrial
and ventricular activation diagnosed by M-mode (10, 13).
AVB-I◦ was assessed only in the recent years, using pulsed
Doppler echocardiography in the left ventricular outflow tract
to record simultaneously mitral valve inflow and aortic outflow
(mitral-aorta), from which the time delay from atrial systole
to ventricular systole could be inferred. AVB-I◦ was diagnosed
when this fetal mechanical Doppler PR interval was found to be
>150ms (16).
DCM was defined as increased size of the left ventricle or
multiple chambers in the absence of chamber wall hypertrophy
with associated decreased contractility on echocardiogram (11,
12); endocardial fibroelastosis as the presence of abnormal
areas of echogenicity on the endocardial surface of the cardiac
chambers and/or valve leaflets on echocardiogram or endocardial
fibrosis on biopsy or autopsy. Hydrops fetalis was defined
as an abnormal accumulation of fluid in at least two fetal
compartments (11, 12).
In each center, autoantibodies tests were performed in a
referral laboratory certified for diagnosis.
Statistical Evaluation
Categorical variables were reported as proportion and/or
percentage, while continuous variables as mean (±SD) values.
Fisher’s exact test or Chi-square test for categorical variables and
Student’s t-test or Wilcoxon-Mann-Whitney test for continuous
variables were applied as appropriate. Multivariate analysis was
not performed due to limited number of cases collected. P <
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0.05 were considered significant and Odds Ratio (OR) with 95%
Confidence Interval (95% CI) was indicated.
RESULTS
Patients
By May 2018, the registry included 89 cases of CHB from 85
patients who had 88 pregnancies. The 85 women were Caucasian
(n = 79, 92.9%), African (n = 3, 3.5%), Asian (n = 2, 2.3%),
and Afro-Caribbean (n = 1, 1.2%) (Table 2). An organ-specific
autoimmune disease was diagnosed in 12 women: autoimmune
thyroiditis (n = 8, 9.4%), celiac disease (n = 3, 3.5%), multiple
sclerosis (n= 1, 1.2%).
Sixty patients reported previous pregnancies, without
previous documented cases of CHB, except for one case of
cutaneous NL. When their first child with CHB was diagnosed,
46 mothers (54.1%) fulfilled the classification criteria for CTDs:
undifferentiated connective-tissue disease (UCTD) (n = 24,
28.2%), SS (n = 18, 21.2%), SLE (n = 4, 4.7%), whereas the
others were considered as anti-SSA/Ro carriers. Few cases of
acquired cardiovascular risk factors were collected: two patients
were smokers, one suffered from hypertension and obesity, and
one had diabetes mellitus.
Four cases of multiple pregnancies were collected: three were
spontaneous dichorionic biamniotic twins, with one affected, and
one unaffected fetus for each pair. The other multiple pregnancy
was a triplet gestation after in vitro fertilization: two out the three
fetuses were affected by CHB (one III and one II degree) and one
unaffected. The triplet pregnancy has already been described (17).
TABLE 2 | Demographic information.
Maternal demography N = 85 (%)
ETHNICITY
Caucasian 79 (92.9)
African 3 (3.5)
Asian 2 (2.3)
Afro-Caribbean 1(1.2)
MATERNAL DIAGNOSIS AT CHB DETECTION
Undifferentiated Connective Tissue Disease 24 (28.2)
Sjögren’s Syndrome 18 (21.2)
Systemic Lupus Erythematosus 4 (4.7)
Carriers of anti-SSA/Ro 24 (28.2)
Carriers of anti-SSA/Ro + anti-SSB/La 15 (17.6)
ASSOCIATED ORGAN-SPECIFIC AUTOIMMUNE DISEASE
Autoimmune thyroiditis 8 (9.4)
Celiac disease 3 (3.5)
Multiple sclerosis 1(1.2)
None/Unknown 73 (85.6)
AUTOANTIBODIES PROFILE
Anti-SSA/Ro 85 (100)
Anti-SSB/La 50 (58.8)
CHB, congenital heart block.
Including the triplet pregnancy, three gestations that occurred
after assisted reproductive technology procedures were collected.
All mothers were anti-SSA/Ro positive by inclusion criteria,
and SSB/La antibodies were present in 58.8%. AntiRo52 status
was available in 58.8% of the mothers, and all were positive.
The mean age at conception was 31.5 years (SD 5.3, range
22–42), 84 cases (94.4%) were diagnosed in utero at a median
term of 21 gestational weeks (gw) (SD 4, range 17–38) and
five (5.6%) were diagnosed in the neonatal period (15). CHB
was initially incomplete in 24 fetuses (five with alternating II-
III degree, two with alternating I-II degree, and 17 II degree).
Considering the highest degree of CHB shown by the fetus/child,
71 (66 in utero and 5 neonatal) (79.8%) third-degree (complete)
CHB, 18 (20.2%) second-degree CHB were included (Table 2).
Fetal/Neonatal Outcomes
Among the 89 cases, 73 (82%) children were born alive at
a mean gestational week (gw) of 35.3 (SD 3.0, range 28–41),
7 elective terminations of pregnancy (TOP) were performed
at a mean term of 22 gw, and nine intra-uterine fetal deaths
occurred at a mean term of 26 gw (Table 3). All the cases
of TOP were CHB grade III. Table 4 reports the univariate
statistical comparison of clinical and demographic features
among survivors at birth and the deceased. By univariate analysis,
factors associated with fetal death were pleural effusion (p =
0.005, OR > 100; CI 95% 2.88->100) and hydrops (p = 0.003,
OR= 14.09; CI 95% 2.01–122).
The five cases diagnosed in the perinatal period or within the
neonatal period (0–27 days after birth) occurred in the 1970–
1980s: all these five newborns had III degree CHB; four of them
received a pacemaker at a mean age of 7.2 years (range 2–18).
Treatment
Prior to CHB identification, only a limited number of patients
were receiving treatments (Table 5), in all cases for maternal
disease: nine were treated with low dose aspirin (LDA), eight with
not-fluorinated steroids, seven with hydroxychloroquine (HCQ),
and one with immunosuppressive therapy (Table 5).
TABLE 3 | Outcomes of 89 cases of CHB.
Pregnancy outcome N = 89 (%)
Live birth 73 (82)
Intrauterine fetal death 9 (10.1)
Termination of pregnancy 7 (7.8)
CHB DETECTION
In utero 84 (94.2)
CHB GRADE
II degree 18 (20.2)
III degree 71 (79.8)
OVERALL MORTALITY 23 (25.8)
In utero 16 (18)
Neonatal 5 (5.6)
Childhood 2 (2.2)
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TABLE 4 | Comparison of clinical and demographic features among children born
alive and fetuses died in utero.
Live birth
n = 68 (%)
Deceased
n = 16 (%)
p-value
IN UTERO DETECTED PATIENTS (84 CASES)
Maternal diagnosis of CTD 37 (54.4) 7 (43.7) 0.44
Non-Caucasian ethnicity 4 (5.4) 2 (12.5) 0.31
Maternal age at conception
(SD)
31 (6.03) 32 (4.16) 0.76
Type of conception
Spontaneous 64 (94.1) 16 (100.0) 0.73
Assisted reproduction
techniques
4 (5.9) 0
Timing of pregnancy
Planned 21 (30.9) 6 (37.5) 0.767
Unplanned/unknown 47 (69.1) 10 (62.5)
Gestational age at detection
(gw) (SD)
22.8 (4.7) 20.7 (1.0) 0.27
Ventricular rate at nadir ≤50
bpm (n = 73)
21 (36.2) 6 (40) 0.78
Mean ventricular rate at
nadir bpm (SD) (n = 73),
44.7 (27.9) 43.5 (30.8) 0.41
CHB grade (n = 84)
II degree 16 (23.5) 2 (12.5) 0.3
III degree 52 (76.5) 14 (87.5)
Impaired left ventricular
function (n = 71)
5 (8.9) 3 (18.7) 0.35
Dilated cardiomyopathy
(n = 74)
10 (12.6) 3 (27.3) 0.39
Hydrops (n = 82) 2 (3.0) 5 (31.2) 0.003*
Pleural effusion (n = 81) 0 3 (18.7) 0.005**
Pericardial effusion (n = 81) 8 (12.3) 5 (31.2) 0.12
Endocardial fibroelastosis
(n = 81)
1 (1.5) 2 (13.3) 0.09
Intrauterine growth
restriction (n = 75)
12 (19.3) 3 (23.1) 0.71
Oligohydramnios (n = 84) 5 (7.8%) 0 0.58
CTD, connective tissue disease; gw, gestational week; bpm, beats per minute; *OR,
14.09; CI 95% 2.01–122, **OR > 100; CI 95% 2.88->100.
After CHB detection, fluorinated steroids (FS) were
administered in 60 (71.4%) pregnancies, with a mean total
duration of treatment of 9.5 weeks (range 4–18 weeks).
Twenty steroid-treated fetuses (33%) received intravenous
immunoglobulin (IVIg) and 17 (28.3%) received cycles with
plasma exchange as well. Sixteen newborns received IVIg at birth.
Effects of treatments in the 60 treated pregnancies were
analyzed and in the majority of the cases no variation in the
progression of CHB was observed (46 cases, 76.7%) (Table 5).
CHB was initially incomplete in 24 fetuses, all of them were
treated at least with FS; five cases of regression from grade
II CHB was observed. In detail: one change occurred from II
degree to variable CHB (alternating between I and II degree),
two from II to I degree and two regression from II degree to no
CHB. Three out of the five fetuses were treated with a combined
protocol composed by fluorinated steroids plus plasmapheresis
TABLE 5 | Therapy before and after CHB detection.
Live birth
n = 73 (%)
Deceased
n = 16 (%)
p-value
THERAPY BEFORE CHB DETECTION
LDA 6 (8.2) 3 (16.6) 0.36
Non-fluorinated steroids 6 (8.2) 2 (12.5) 0.67
Hydroxychloroquine 7 (9.6) 0 0.33
DMARDs 0 (0) 1 (6.2) 0.19
MATERNAL THERAPY AFTER FETAL CHB DETECTION (n = 84)
Live birth
n = 68 (%)
Deceased
n = 16 (%)
p-value
Any treatment 50 (73.5) 10 (62.5) 0.46
Fluorinated steroids 50 (73.5) 10 (62.5) 0.46
Intravenous
Immunoglobulin
18 (26.4) 2 (12.5) 0.41
Plasma exchange 16 (23.5) 1 (6.2) 0.28
Other (beta-mimetics) 6 (8.9) 1 (6.2) 0.81
CHB VARIATION DURING/AFTER THERAPY (n = 60)
Live birth
treated
n = 50 (%)
Deceased
treated
n = 10 (%)
p-value
Regression 5 (10) 0 0.74
Progression 3 (6) 1 (10)
Unchanged 38 (76) 8 (80)
Unknown 4 (8) 1 (10)
LDA, low dose aspirin; DMARDS, immunosuppressive therapy.
plus IVIg, 1 received dexamethasone plus plasmapheresis, and
one only dexamethasone.
Fourteen cases of newborns small for gestational age,
five cases of intrauterine growth retardation, four cases
of olygohydramnios, one case of maternal hypertension
were recorded in the 60 mothers treated with FS; these
complications may be related to the treatment with FS,
particularly olygohydramnios and hypertension.
Postnatal Outcomes
Among the 73 live births, five newborns died within 10 days after
birth (Table 6). These five children were born prematurely and in
four cases death occurred even if a pacemaker was placed at birth.
Out of the remaining 68 children, two died later, one due to
late onset DCM at the age of 21months after a PM placed at birth,
and 1 at the age of 6 years for a sudden death, probably due to a
thrombotic event, however autopsy was not performed. Another
child underwent cardiac transplantation at the age of 17 months
for late onset DCM in 2003, and at present he is doing well.
Overall DCM was recorded in six cases at birth, while two
cases of late onset DCM were observed (2.2%) (see Table 1). All
the children with DCM were permanently paced, and two of
them died (25%).
Overall a PM was placed in 51 of the 73 children born alive
(69.8%): 19 (37.2%) at birth, 10 (19.6%) within the first month of
life, 11 (21.5%) within the first year of life, and 11 later (21.5%).
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TABLE 6 | Pregnancy outcome and postnatal follow-up in pregnancies ended
with a live birth.
Pregnancy outcome Live birth n = 73 (%)
Medium gestational week of delivery (SD) (n = 70) 35.3 (3.0)
Delivery (n = 73)
Cesarean section 58 (82.3)
Vaginal 12 (17.1)
unknown 3 (6)
Preterm deliveries <37 weeks 53 (72.6)
Preterm deliveries <34 weeks 26 (35.6)
Sex (n = 71)
Female 44 (62)
Male 27 (38)
Medium weight at birth (grams) (SD) (n = 69) 1776.5 (523.5)
Medium length (cm) (SD) (n = 40) 40.5 (5.8)
APGAR (1–10) (n = 55) 8.5 (1)
DCM at birth (n = 72) 5 (7.0)
POSTNATAL OUTCOME
At birth/Neonatal PM implantation 29 (39.7)
Neonatal death 5 (6.8)
Infant/childhood PM implantation 22 (30.1)
Infant/childhood death 2 (3.1)
Overall PM pacing 51 (69.8)
Overall mortality 23 (25.8)
DCM, dilated cardiomyopathy; PM, pacemaker.
Within the first year of life, more than 50% of the surviving
children were paced (40 children, 54.8%).
Recurrence
After the index pregnancy, 14 women had 17 subsequent
pregnancies (reviewed in Table 7): three were complicated
by a CHB therefore the recurrence rate in our cohort was
17.6%. Nine patients received treatments during 10 pregnancies
(58.8%): hydroxychloroquine in 1, IVIg alone in 1, not-
fluorinated steroids (for maternal indication) alone in 3, not-
fluorinated steroids and IVIg in 3, IVIg and HCQ in 1,
and IVIg with plasmapheresis and fluorinated steroids in 1.
Non fluorinated steroids and HCQ were administered before
pregnancy, fluorinated steroids were introduced at conception in
two cases, and IVIG and plasmapheresis were started from week
12 (see Table 7 for details).
Adverse events possibly related with a prolonged use of
steroids (maternal hypertension, intra-uterine growth restriction,
oligohydramnios) occurred in three. The recurrence rate was not
statistically different in mothers who received steroids compared
to those who did not (28.6 vs. 11.1%, respectively, p = 0.55), but
the numbers are low. All the three recurrences of CHB occurred
after an index pregnancy complicated with fetal or neonatal death
due to a complete CHB.
Maternal Follow-Up
At the time of index pregnancy, 39 patients were considered as
asymptomatic autoantibodies carriers. Two years after the latest
pregnancy, 11 patients of them developed signs/symptoms that
fulfilled the criteria for connective tissue disease: six cases of
UCTD and five of SS. In six patients, a chronic treatment was
required: oral steroids in four, HCQ in three, and methotrexate
in one.
DISCUSSION
This paper describes the first data from the Italian Registry
of neonatal cardiac lupus syndrome, including 89 retrospective
cases of CHB associated with anti-SSA/Ro and/or anti-SSB/La
antibodies. This registry was created in order to collect the cases
diagnosed and treated in different Centers, some of them with
a longstanding interest in this rare condition. Although some of
the cases included in this registry have been already published
(17–20), this remains the first effort to analyze all the data as a
collaborative national study.
The results that were obtained are in many aspects in line
with the published large retrospective studies (Table 1) (9–
13). The number of cases of complete and incomplete CHB
(79.8 vs. 20.2%) and the cumulative probability of pacemaker
implantation, almost 70%, were very similar to already published
data (1, 9–13) (see Table 1).
The risk of fetal mortality in the present cohort was 18% and
the overall mortality was 25.8%, slightly higher in our cohort
than reported in other publications (see Table 1). On statistical
analysis, several risks factors that were associated or had a trend
toward an increased risk for mortality were confirmed. The
presence of hydrops and fetal serositis are well established risk
factors for adverse outcome, confirmed in several previous papers
(1, 11, 12). No other risk factors were identified in our cases,
in particular fetal mortality was not associated with a maternal
diagnosis of SLE or SS at the time of pregnancy or a specific
ethnicity as previously reported (11).
Some confusion existed in the past on the definition of
“congenital” heart block, with some cases detected after birth;
for this reason a multidisciplinary group proposed to define
congenital heart block as an atrioventricular block diagnosed in
utero, at birth or within the neonatal period (15) and in the
present report five cases were diagnosed after birth.
In our registry data on subsequent pregnancies after a case
of CHB were also collected; recurrence rate of CHB was 17.6%,
strikingly similar to what found (17.4%) (7) in the American
Research Registry for Neonatal Lupus; in our registry all the three
fetuses with recurrent CHB were born alive.
Till date, the management of CHB remains very controversial
and there are no generalized recommendations on how to treat
CHB or if a prophylactic treatment is required during pregnancy.
Various treatment approaches have been reported, including
steroids, plasmapheresis, IVIg, several immunosuppressive
agents, and hydroxychloroquine (21). Fluorinated steroids (FS)
could cross the placenta because they are only partially
inactivated by 11ß-hydroxysteroid dehydrogenase complex
expressed in syncytial trophoblast cells and have satisfactory
bioavailability to the fetus (22), and are the drugs with
the largest clinical experience. Side effects of high dose
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TABLE 7 | Subsequent pregnancies after an index pregnancy complicated with CHB: treatment and pregnancy outcomes.
Index pregnancy
outcome
Maternal
diagnosis
Year of
pregnancy
Fetal
ECHO
Treatment Pregnancy
outcome
Pregnancy
complications
Pt 1 CHB III degree, born
alive
SS 2005 yes Prednisolone 28 mg/w
IVIg 400mg/kg every 3w
between 12 and 24th gw
Born alive,
without CHB
no
Pt 2 CHB III degree,
neonatal detection,
infant death
SS 1978 yes no Neonatal CHB III
degree
no
Pt 3 CHB III degree, born
alive
Carrier
anti-SSA/Ro
2014 yes no Born alive,
without CHB
no
Pt 4 CHB III degree, infant
death
UCTD 2003 yes no Born alive,
without CHB
no
2006 yes no Born alive,
without CHB
no
Pt 5 CHB II degree, born
alive
SS 2007 yes IVIg 400 mg/kg every 3w
between 12 and 24th gw
HCQ 200 mg/daily
Born alive,
without CHB
no
Pt 6 CHB III degree, TOP UCTD 2006 yes Prednisone 35 mg/w; IVIg
400 mg/kg every 3w
between 12 and 24th gw
Born alive,
without CHB
Polyhydramnios
2008 yes Prednisone 25 mg/w; IVIg
400 mg/kg every 3w
between 12 amd 24h gw
Born alive,
without CHB
Maternal
hypertension
Pt 7 CHB III degree, TOP SS 2002 yes Prednisone 35 mg/w; Born alive,
without CHB
no
2009 yes no Born alive,
without CHB
no
Pt 8 CHB III degree,
intra-uterine fetal
death
Carrier
SSA/Ro
+SSB/La
2012 yes Betametasone 28 mg/w,
IVIg 1 g/kg every 2w for
13w, Plasmapheresis for
14w
CHB II degree Olygo-
anydramnios
Pt 9 CHB III degree, born
alive
UCTD 1999 yes Betametasone 10 mg/w Born alive,
without CHB
IUGR, maternal
hypertension
Pt 10 CHB III degree,
intra-uterine fetal
death
Carrier
SSA/Ro
+SSB/La
2001 yes Dexametasone 28 mg/w CHB III degree PM at birth
Pt 11 CHB III degree, TOP UCTD 2007 yes IVIg400 mg/kg every 3w
between 12 and 24th gw
Born alive,
without CHB
Pt 12 CHB III degree, born
alive
Carrier
SSA/Ro
+SSB/La
2015 yes no Born alive,
without CHB
Pt 13 CHB III degree,
intra-uterine fetal
death
UCTD 2014 yes HCQ Born alive,
without CHB
Oligohydramnios
We did not include in the table one case that ended with an early termination of pregnancy required by parents at 11 gw. ECHO, echocardiography; HCQ, hydroxychloroquine;
TOP, termination of pregnancy; PM, pacemaker; UCTD, undifferentiated connective tissue disease; SS, Sjögren Syndrome; IUGR, intra-uterine growth restriction; IVIg, intravenous
immunoglobulin; HCQ, hydroxychloroquine.
FS during pregnancy may be important: increased blood
pressure, osteopenia, osteonecrosis, susceptibility to infections,
gestational diabetes, premature rupture of the membranes
and olygohydramnios. In the present study 60 women were
treated with FS: olygohydramnios occurred in 6.6% of cases,
intrauterine growth retardation in 8.3% and hypertension
in 1.7%.
Retrospective data over a wide time span ranging from
the 1970s through 2017 were collected in the present study,
therefore the treatment strategies were very heterogeneous.
Steroids resulted as the most used drugs, reaching the highest
rate compared with other registries (see Table 1) and this
result confirms that there is no consensus regarding treatment
with steroids. Moreover, in many occasions, it depends on the
historical approach followed in the single center (23): some
centers treated no patients, irrespective of the fetal status,
whereas in others hospitals FS were used almost in all cases.
The most consistent data on the possible efficacy in CHB were
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published by Jaeggi et al. (24) in 2004. The authors reported a
higher one-year survival rate and less complications or features
associated with NL in 21 treated complete CHB compared
with 11 patients who did not receive FS. This study, however,
displays some limitations. Firstly, the authors compared fetuses
from two different eras: the historical cohort from 1990 to
1996 did not receive steroids, whereas all fetuses between 1997
and 2003 were treated. A second important limitation was
the higher rate of risk factors for a poor prognosis present
in the untreated cohort. Subsequent works did not confirm
these findings (10–12, 25). In fact, we also did not find any
significant differences on fetal mortality between the groups
treated and not with FS, which is consistent with the large
international series.
In particular Izmirly et al. (25) compared 71 fetuses
with isolated CHB who received FS within 1 week of
detection with 85 who received no treatment and evaluated
the development of EFE, dilated CMP, hydrops, mortality,
and PM implantation. These authors observed that FS did
not significantly prevent development of disease beyond
the atrio-ventricular node [adjusted Hazard Risk (HR) =
0.90; p = 0.77], nor reduce mortality (HR = 1.63; p =
0.47), or forestall/prevent PM implantation (HR = 0.87;
p = 0.53), so they concluded that no evidence supports
fluorinated steroids to prevent disease progression or death in
isolated CHB.
Another possible indication for the use of FS is for the
prevention of the evolution from incomplete to complete
CHB. Whereas, complete CHB is considered irreversible,
regression from incomplete block after treatment has been
described (10, 11, 26–28). In our cohort an improvement was
observed in five cases, all treated with FS and three treated
with a combination therapy recently published (29). In brief,
in that paper (29) the authors wanted to summarize the
possible effects of each single procedure: they demonstrated
that plasmapheresis could remove anti/SSA-Ro autoantibodies
(30), FS could reduce local inflammation and IVIg could
limit the effects of autoantibodies. They used this approach in
12 patients with second or third degree CHB. No variation
occurred in the six cases with complete CHB, whereas an
improvement occurred in 50% of second degree CHB. The
authors reported no side effects in the fetuses or in the
mothers, proposing this combination therapy as a therapeutic
option in second degree CHB. Unfortunately, since such
improvement has been observed also in the absence of any
treatment (12) or only with FS, it is not possible to draw
any definite conclusion. The recent paper by Cuneo et al.
(28) underlines as timing may very relevant for a possible
therapeutical windows.
Several hypotheses have been proposed showing the
potential usefulness of IVIG to prevent cardiac tissue damage:
firstly increasing the elimination of maternal autoantibodies
through IVIG saturation, secondly decreasing placental
transport of autoantibodies through FcγRn leading to
the modulation of inhibitory signaling on macrophages,
with consequent reduction of the inflammatory response
and fibrosis. This explain the patients treated during
pregnancies and the 16 newborns treated immediately after
birth (31–33).
There are no specific guidelines for the prevention of
recurrence of CHB in subsequent pregnancies and this explains
the extreme heterogeneity of treatment that was observed in
this cohort, ranging from only clinical and echocardiography
monitoring to combined therapies during pregnancy. Non-
fluorinated steroids do not cross the placenta and would
not be useful at all. Intravenous immunoglobulin has been
proposed in the prevention of recurrence in small case
series and in two prospective studies that were performed
in Europe and in United States (34, 35) with a similar
protocol (400 mg/kg every 3 weeks from 12 to 24 gw).
Four of our cases were included in the European trial. Both
the studies were terminated early because of an unchanged
prevalence of recurrence and it was concluded that IVIg at the
proposed dose was ineffective at reducing the recurrence rate of
cardiac NL.
In the last years, the use of HCQ was shown to
be a possible approach to the secondary prevention of
the recurrence of CHB. Retrospective analysis from an
international cohort (36) reported a higher recurrence rate
in pregnancies not treated with HCQ compared with those
treated with HCQ. In our study only a limited number
of pregnancies were exposed to HCQ not allowing any
possible further analysis. However, since the use of HCQ
is compatible with pregnancy (37) and is generally a well-
tolerated drug, it may be proposed in patients with known
antibody positivity.
Our study has several limitations. Data were collected
retrospectively and in some pregnancies not all of the data were
available, which limits the power of our statistical analysis. It is
well established that the distinction between II and III degree AV
block in uteromay be difficult, problematic and time consuming
and, when revised centrally, some diagnoses of II degree might
be reclassified as III degree and viceversa (13). For this paper
it was not possible to reassess the diagnosis centrally therefore
some complete CHB could be misdiagnoses as incomplete (13).
CHB cases whose mothers were anti-SSA/Ro negative were
not included (17). This first report of the registry is mainly
driven by rheumatological centers, and some geographical Italian
regions are not represented; only the centers whose ethical
committees approved the study enrolled cases for this initial
analysis. This peculiarity might also explain why in our registry
the majority of the mothers already had a diagnosis of CTD
at the time of the index pregnancy, an evidence that differs
from other experiences. The syndrome of course requires a
multidisciplinary approach, not only for the clinical management
of each case but also for the systematic collection of the data
and their analysis. Pediatric cardiologists and gynecologists play
a fundamental role in the management of this condition, and it
is planned to involve them in further collections and analyses
of data.
In conclusion, this is the first preliminary report of the
data from the Italian Registry of neonatal cardiac lupus
syndrome, that was established in 2016. Italian centers showed
an heterogenous pattern of management of CHB fetuses, with
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some centers treating all cases with FS and some centers
treating no cases. The establishment of this registry might
help to share the data, to make more homogenous the
management of this rare condition and to stimulate further
multidisciplinary studies.
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